Financials in USD. Standardized financial statements.
A compact view of how BioAtla, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.00M | $11.00M | $0 | $0 | $250,000 | $429,000 | $5.20M | $10.63M |
| Revenue Growth? | -81.8% | 0.0% | 0.0% | -100.0% | -41.7% | -91.8% | -51.1% | 0.0% |
| Cost of Revenue? | $0 | $925,000 | $1.22M | $1.20M | $0 | $19.93M | $25.92M | $26.30M |
| Gross Profit? | $2.00M | $10.07M | -$1.22M | -$1.20M | $250,000 | -$19.50M | -$20.72M | -$15.68M |
| Gross Margin? | +100.0% | +91.6% | 0.0% | 0.0% | +100.0% | -4546.4% | -398.4% | -147.5% |
| Operating Expenses? | $61.30M | $84.02M | $128.47M | $106.94M | $96.69M | $10.60M | $7.55M | $38.86M |
| Operating Income? | -$59.30M | -$73.94M | -$129.69M | -$108.14M | -$96.44M | -$30.10M | -$28.27M | -$28.23M |
| EBITDA? | -$58.93M | -$73.02M | -$122.24M | -$105.28M | -$94.07M | -$33.46M | -$27.41M | -$27.24M |
| Income Before Tax | -$59.61M | -$69.78M | -$123.46M | -$106.48M | -$95.40M | -$35.85M | -$29.86M | -$28.98M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $204,000 |
| Net Income? | -$59.61M | -$69.78M | -$123.46M | -$105.28M | -$95.40M | -$35.85M | -$29.79M | -$28.98M |
| EPS? | $-50.50 | $-72.00 | $-129.00 | $-137.00 | $-138.00 | $-53.00 | $-46.50 | $-67.00 |
| Diluted EPS? | $-50.50 | $-72.00 | $-129.00 | $-137.00 | $-138.00 | $-53.00 | $-46.50 | $-67.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality